Eledon Pharmaceuticals (NASDAQ:ELDN) Releases Earnings Results, Misses Expectations By $0.02 EPS

Eledon Pharmaceuticals (NASDAQ:ELDN) posted its quarterly earnings data on Tuesday. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02), Zacks reports.

Eledon Pharmaceuticals Trading Down 3.3 %

Shares of Eledon Pharmaceuticals stock opened at $4.13 on Friday. The company has a market cap of $163.80 million, a P/E ratio of -2.05 and a beta of 0.76. The business has a 50-day moving average price of $3.23 and a two-hundred day moving average price of $2.88. Eledon Pharmaceuticals has a 1-year low of $1.11 and a 1-year high of $5.54.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).